Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through its wholly-owned subsidiary Leonard-Meron Biosciences, Inc. (LMB) and majority-owned subsidiaries Citius Oncology, Inc. (CTOR) and NoveCite, Inc. Citius Oncology, which holds the rights to the commercialized product LYMPHIR (denileukin diftitox), became a standalone publicly traded company in August 2024 but remains a majority-owned subsidiary of Citius Pharma (approx. 62% ownership as of June 30, 2026).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Nine Months Ended June 30, 2026 |
|---|---|---|
| Revenues | $1,493,788 | $7,105,197 |
| Gross Profit | $1,001,945 (67% margin) | $5,495,268 (77% margin) |
| Net Loss | $(11,919,260) | $(49,422,895) |
| Net Loss Attributable to Common Stockholders | $(8,862,843) | $(38,314,768) |
| Net Loss Per Share (Basic & Diluted) | $(0.34) | $(1.64) |
| Cash and Cash Equivalents (End of Period) | $17,007,523 | |
| Working Capital | $(8,317,988) (Negative) | |
| Total Debt (Notes Payable, net) | $6,410,161 |
Note: Revenue generation commenced in December 2025 following the commercial launch of LYMPHIR. Prior periods had zero revenue.
Material Changes vs. Prior Period
- Revenue Growth: The company generated $1.49 million in revenue for the quarter and $7.1 million for the nine months ended June 30, 2026, compared to zero in the prior year periods. This is driven by the commercial sales of LYMPHIR.
- Operating Expenses: Total operating expenses increased significantly to $12.7 million (quarter) and $58.4 million (nine months) compared to $8.8 million and $30.1 million in the prior year periods. The nine-month increase was primarily driven by a $19.7 million contract cancellation fee recorded in March 2026 following the termination of a contract manufacturing organization (CMO) agreement due to payment breaches, as well as costs associated with expanding the commercial organization.
- Amortization: Amortization of in-process research and development (IPR&D) began in December 2025 upon revenue generation. For the nine months ended June 30, 2026, amortization expense was $4.0 million, compared to zero in the prior year.
- Financing Activities: The company raised significant capital through equity offerings and debt. In April 2026, Citius Pharma raised ~$4.5 million via a registered direct offering. In May 2026, Citius Oncology raised ~$9.7 million via warrant exercises and secured a $10 million term loan (with up to $15 million additional tranches available upon milestone achievement).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Uncertainty: The filing includes a substantial doubt about the company's ability to continue as a going concern. Management estimates cash resources will be sufficient only through November 2026. Additional capital is required to fund operations beyond this date.
- Commercial Outlook: Management reports positive early launch metrics for LYMPHIR, including 44 institutions ordering the product, 83% of target accounts progressing formulary reviews, and broad payer coverage (135 health plans). International distribution has begun in Europe and the Middle East via Named Patient Programs.
- Debt Risks: Citius Oncology's new term loan is secured by substantially all of its assets, including intellectual property. Failure to meet revenue milestones could prevent access to additional funding tranches. The loan carries a high interest rate (greater of Prime + 6% or 12.75%) and includes a balloon payment at maturity.
- Nasdaq Compliance: Both Citius Pharma and Citius Oncology received notices of non-compliance with the Nasdaq minimum bid price rule ($1.00 per share) in early 2026. They have been granted compliance periods to regain standing (Citius Pharma until August 10, 2026; Citius Oncology until October 19, 2026).
- Unusual Items: The nine-month results include a one-time gain of $3.8 million from the sale of New Jersey net operating losses. Conversely, the results were negatively impacted by the aforementioned $19.7 million CMO termination fee.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to raise capital before November 2026 to avoid insolvency, given the negative working capital of ~$8.3 million.
- Debt Covenants: Review the specific revenue and liquidity milestones required to unlock the remaining $15 million of the Citius Oncology term loan.
- CMO Transition: Confirm the status of the new contract manufacturing agreement entered into in June 2026 to ensure no interruption in LYMPHIR supply.
- Outstanding Milestone Payments: Note the remaining $15.65 million milestone payment due to Dr. Reddy's Laboratories and approximately $6.3 million in unpaid invoices to Eisai.
- Dilution: Assess the impact of outstanding warrants (over 53 million for Citius Oncology and 23 million for Citius Pharma) and the potential conversion of loan principal into equity.